AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections. The antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback